logo
Twitter
Discord
Email
logo
PureTech Health plc

PureTech Health plc

NASDAQ•PRTC
CEO: Dr. Bharatt M. Chowrira J.D., Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-11-16
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Contact Information
6 Tide Street, Suite 400, Boston, MA, 02210, United States
617-482-2333
www.puretechhealth.com
Market Cap
$398.78M
P/E (TTM)
7.6
40.6
Dividend Yield
--
52W High
$21.75
52W Low
$13.30
52W Range
38%
Rank63Top 84.3%
2.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q2 2025 Data

Revenue

$1.85M+542.71%
4-Quarter Trend

EPS

-$1.90+26.67%
4-Quarter Trend

FCF

-$45.94M-42.58%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Revenue Growth Accelerates Total revenue reached $4.83M USD in 2024, marking a strong 45.0% increase from $3.33M USD reported in 2023.
Profitability Reversal Achieved Net income swung to $53.51M USD profit for owners in 2024, successfully reversing the $65.70M USD loss reported previously.
Strong Liquidity Position Available funds totaled $367.31M USD by year-end 2024, bolstered by a $151.81M USD gain from Seaport deconsolidation.

Risk Factors

Substantial Funding Required Requires substantial additional funding to achieve goals; failure risks delaying or terminating critical therapeutic development efforts.
Clinical Development Uncertainty Therapeutic candidates remain in preclinical or clinical stages with uncertain outcomes, potential delays, and high associated costs.
Regulatory Approval Hurdles Obtaining regulatory clearance, certification, or approval for candidates is uncertain and necessary before commercialization can occur.
Intellectual Property Risks Ability to protect intellectual property rights globally is not guaranteed, potentially impairing commercialization capabilities for key assets.

Outlook

Advance Key Therapeutic Candidates Focus remains on clinical development progress for LYT-100 (IPF) and LYT-200 (immuno-oncology) programs through trials.
Manage Founded Entity Value Ability to realize value from Founded Entities may be impacted by ownership changes or contractual agreements with investors.
Capital Structure Management Expectations related to capital use, future revenues, and capital requirements necessitate ongoing assessment for financing needs.

Peer Comparison

Revenue (TTM)

Autolus Therapeutics plcAUTL
$51.13M
+330.9%
XOMA Royalty CorporationXOMA
$40.73M
+88.5%
Lineage Cell Therapeutics, Inc.LCTX
$10.82M
+24.1%

Gross Margin (Latest Quarter)

XOMA Royalty CorporationXOMA
90.6%
-9.4pp
Korro Bio, Inc.KRRO
17.8%
+0.0pp
Lineage Cell Therapeutics, Inc.LCTX
0.0%
+0.0pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
RAPT$548.71M-8.5-61.8%1.6%
DBVT$539.44M-4.8-287.1%0.0%
FDMT$430.13M-2.5-47.3%5.3%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
118.0%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Apr 28, 2026
|
EPS:-
|
Revenue:-
Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Apr 30, 2025|
    Revenue: $4.83M+45.0%
    |
    EPS: $2.00+183.3%
    N/A

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 25, 2024|
    Revenue: $3.33M+59.3%
    |
    EPS: $-2.40-33.3%
    Meet

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Apr 28, 2023|
    Revenue: $2.09M-79.1%
    |
    EPS: $-1.80+14.3%
    Meet

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Apr 26, 2022|
    Revenue: $9.98M+19.6%
    |
    EPS: $-2.10-1150.0%
    Meet

  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Apr 15, 2021|
    Revenue: $8.34M-4.0%
    |
    EPS: $0.20-98.7%
    Miss